Recombinant Human F13A1 His-tag Protein, CF Summary
Details of Functionality |
Measured by its ability to release DNP from Abz-NE(CAD-DNP)EQVSPLTLLK-OH. The specific activity is >13.0 pmol/min/μg, as measured under the described conditions. |
Source |
Spodoptera frugiperda, Sf 21 (baculovirus)-derived human F13A1 protein Ser2-Met732 with an N-terminal Met and 6-His tag
|
Accession # |
|
N-terminal Sequence |
No results obtained, Met predicted. Protein identity confirmed by MS analysis of tryptic fragments.
|
Protein/Peptide Type |
Recombinant Enzymes |
Purity |
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. |
Endotoxin Note |
<0.10 EU per 1 μg of the protein by the LAL method. |
Applications/Dilutions
Dilutions |
|
Theoretical MW |
84 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
SDS-PAGE |
76-88 kDa, under reducing conditions
|
Packaging, Storage & Formulations
Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 6 months from date of receipt, -70 °C as supplied.
- 3 months, -70 °C under sterile conditions after opening.
|
Buffer |
Supplied as a 0.2 μm filtered solution in Tris, NaCl, EDTA, Glycerol and TCEP. |
Purity |
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. |
Assay Procedure |
- Assay Buffer: 50 mM Tris, 150 mM NaCl, 10 mM CaCl2, 0.05% Brij-35, pH 7.5 (TCNB)
- Recombinant Human F13A1 (rhF13A1) (Catalog # 10179-F1)
- Recombinant
Human Coagulation Factor II/Thrombin (Catalog # 1473-SE)
- Substrate: Abz-NE(CAD-DNP)EQVSPLTLLK-OH (Zedira, Catalog # A101), 5 mM stock in DMSO
- F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
- Florescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent
- Activate rhF13A1 at 100 µg/mL with 40 µg/mL rhThrombin in Assay Buffer for 30 minutes at 37 °C.
- Dilute activated rhF13A1 to 20 µg/mL in Assay Buffer.
- Dilute Substrate to 100 µM in Assay Buffer.
- Load in plate 50 µL of 20 µg/mL activated rhF13-A1, and start the reaction by adding 50 µL of 100 µM Substrate. Include a Substrate Blank containing 50 µL Assay Buffer and 50 µL of 100 µM Substrate.
- Read at excitation and emission wavelengths at 313 nm and 418 nm, respectively, in kinetic mode for 5 minutes.
- Calculate specific activity:
Specific Activity (pmol/min/µg) = | Adjusted Vmax* (RFU/min) x Conversion Factor** (pmol/RFU) | amount of enzyme (µg) |
*Adjusted for Substrate Blank **Derived using calibration standard Abz-Gly-OH (Bachem, Catalog # E-2920) Per Well: - rhF13A1: 1 µg
- Substrate: 50 µM
|
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Recombinant Human F13A1 His-tag Protein, CF
Background
Coagulation Factor XIIIa1 (F13a1) is a member of the transglutaminase family which includes F13A1 and TGM1-7 (1). F13 in the plasma is a tetrameric complex composed of two alpha (A) and two beta (B) chains where the A subunit is a transglutaminase zymogen and the B subunit is an inhibitory glycoprotein with no enzymatic function (2). Activation by thrombin and calcium ions results in the formation of the catalytically active transglutaminase F13a composed of an alpha chain homodimer capable of forming gamma-glutamyl-epsilon-lysine cross-links. The 83 kDa F13a monomer has an N-terminal activation peptide and a beta sandwich preceding the catalytic core with catalytic triad active site and two C-terminal beta barrels (3). The active homodimer is intracellular in platelets, megakaryocytes, monocytes and macrophages. The primary physiological outcome of the catalytic activity of F13a is cross-linking of fibrin and anti-plasmin to stabilize the fibrin clot (4,5). However, in addition to cross-linking fibrin, F13a is capable of cross-linking many substrates involved in complement activation, coagulation, inflammatory and immune responses and extracellular matrix organization (6). Cross-linking of key substrates by F13a has been directly shown to play a role in in atherosclerosis (7), wound healing (8), angiogenesis (9,10), maintaining pregnancy (11), ECM deposition, osteoblast differentiation and bone remodeling (12), and immune defense (13). F13A has also been detected as a marker in acute promyelocytic leukemia (APL)(14) and expression is considered of value for diagnosis and prognosis for leukemia-associated immunophenotype. Congenital deficiency results in bleeding manifestations including intercranial hemorrhage (15), poor wound healing (17), and spontaneous abortions (17) that can be treated with F13 (18).
- Griffin, M. et al. (2002) Biochem. J. 368:377.
- Muszbek, L. et al. (1999) Thromb. Res. 94:271.
- Yee, V. C. et al. (1994) Proc. Natl. Acad. Sci. USA 91:7296.
- Lord, S. T. et al. (2011) Aterioscler. Thromb. Vasc. Biol. 31:494.
- Fraser, S. R. et al. (2011) Blood 117:6371.
- Nikolajsen, C. L. et al. (2014) J. Biol. Chem. 289:6526.
- AbdAlla, S. et al. (2004) Cell. 119:343.
- Nahrendorf, M. et al. (2006) Circulation 113:1196.
- Dardik, R. et al. (2006) Thromb. Haemost. 95:546.
- Dardik, R. et al. (2005) Arterioscler. Thromb. Vasc. Biol. 25:526
- Asahina, T. et al. (2000) Placenta. 21:388.
- Piercy-Kotb, S. A. et al. (2012) J. Cell Physiol. 227:2936.
- Richardson, V. R. et al. (2012) Br. J. Haematol. 160:116.
- Simon, A. et al. (2012) Cytometry B. Clin. Cytom. 82:209.
- Naderi, M. et al. (2015) Hematology. 20:112.
- Inbal, A. et al. (2005) Thromb. Haemost. 94:432.
- Inbal, A. and L. Muszbek. (2003) Semin. Thromb. Hemost. 29:171
- Naderi, M. et al. (2016) Iran J. Pharm. Res. 15:635.
Customers Who Viewed This Item Also Viewed...
Species: Rt
Applications: IHC, WB
Species: Hu, Mu, Rt
Applications: IP, KO, Simple Western, WB
Species: Hu, Mu, Rt
Applications: Dual ISH-IHC, EM, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
Species: Bv, Ca, Ch, Eq, Hu, Mu, Po, Rt
Applications: ICC/IF, IHC, IHC-Fr, IHC-P, WB
Species: Bv, Ca, Eq, Fe, Hu, Mu, Po, Rt
Applications: ICC/IF, IHC, IHC-Fr, IHC-P, Simple Western, WB
Species: Hu, Mu
Applications: Flow-IC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
Species: Hu
Applications: BA
Species: Hu
Applications: CyTOF-ready, ELISA, Flow, ICC/IF, IHC, IHC-P, PA, WB
Species: Hu, Mu
Applications: IHC
Species: Hu, Rt
Applications: ELISA, WB
Species: Hu, Mu, Rt
Applications: ICC/IF, IHC, IHC-P, WB
Species: Hu, Mu
Applications: IHC, IHC-P, WB
Species: Hu, Mu
Applications: ELISA, Flow, ICC/IF, IHC, IHC-Fr, IHC-P
Species: Hu
Applications: BA
Species: Ca, Fe, Hu, Mu
Applications: Dual ISH-IHC, ICC/IF, IHC, IHC-Fr, IHC-P
Species: Hu, Mu
Applications: IHC, IHC-P, WB
Species: Hu, Mu, Rt
Applications: CyTOF-ready, Flow, ICC, IHC, Simple Western, WB
Species: Hu, Mu, Rt
Applications: ICC/IF, IHC, IHC-P, KD, WB
Species: Hu, Mu, Rt
Applications: ELISA, ICC/IF, IHC, IHC-P, WB
Species: Hu
Applications: ELISA
Publications for Factor XIIIa (10179-F1) (0)
There are no publications for Factor XIIIa (10179-F1).
By submitting your publication information earn gift cards and discounts for future purchases.
Reviews for Factor XIIIa (10179-F1) (0)
There are no reviews for Factor XIIIa (10179-F1).
By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
- Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
- Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
FAQs for Factor XIIIa (10179-F1) (0)
Additional Factor XIIIa Products
Blogs on Factor XIIIa